Purdue Pharma
CT - Stamford
Pharmaceutical2 H-1B visas (FY2023)Focus: Small Molecules
Purdue Pharma is a life sciences company focused on Small Molecules.
Neurology
Total Funding
$NaNM
Open Jobs
0
Products & Portfolio (5)
7 discontinued products not shown
BUTRANS
buprenorphine
LOE Approaching
TRANSDERMAL · FILM, EXTENDED RELEASE
Partial Opioid Agonists
severepersistent painincluding immediate-release opioids
2010
30
MS CONTIN
morphine sulfate
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of morphine is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with morphine. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
severepersistent painincluding immediate-release opioids
1987
30
NALMEFENE HYDROCHLORIDE
nalmefene hydrochloride
Post-LOE
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
CLINICAL PHARMACOLOGY Pharmacodynamics Nalmefene hydrochloride injection prevents or reverses the effects of opioids, including respiratory depression, sedation, and hypotension. Pharmacodynamic studies have shown that nalmefene hydrochloride injection has a longer duration of action than naloxone at fully reversing doses. Nalmefene hydrochloride injection has no opioid agonist activity. Nalmefene hydrochloride injection is not known to produce respiratory depression, psychotomimetic effects, or pupillary constriction. No pharmacological activity was observed when nalmefene hydrochloride injection was administered in the absence of opioid agonists. Nalmefene hydrochloride injection has not been shown to produce tolerance, physical dependence, or abuse potential. Nalmefene hydrochloride injection can produce acute withdrawal symptoms in individuals who are opioid dependent. Pharmacokinetics Nalmefene exhibited dose proportional pharmacokinetics following intravenous administration of 0.5 mg to 2 mg. Pharmacokinetic parameters for nalmefene after a 1 mg intravenous administration in adult male volunteers are listed in Table 1. Table 1: Mean (CV%) Nalmefene Pharmacokinetic Parameters In Adult Males Following a 1 mg Intravenous Dose Parameter Young, N=18 Elderly, N=11 Age 19 to 32 62 to 80 C p at 5 min. (ng/mL) 3.7 (29) 5.8 (38) V dss (L/kg) 8.6 (19) 8.6 (29) V c (L/kg) 3.9 (29) 2.8 (41) AUC 0-inf (ng-hr/mL) 16.6 (27) 17.3 (14) Terminal T 1/2 (hr) 10.8 (48) 9.4 (49) Cl plasma (L/hr/kg) 0.8 (23) 0.8 (18) ABSORPTION Nalmefene was completely bioavailable following intramuscular or subcutaneous administration in 12 male volunteers relative to intravenous nalmefene. The relative bioavailabilities of intramuscular and subcutaneous routes of administration were 101.5% ± 8.1% (Mean ± SD) and 99.7% ± 6.9%, respectively. Nalmefene will be administered primarily as an intravenous bolus, however, nalmefene can be given intra-muscularly (IM) or subcutaneously (SC) if venous access cannot be established. While the time to maximum plasma nalmefene concentration was 2.3 ± 1.1 hours following intramuscular and 1.5 ± 1.2 hours following subcutaneous administrations, therapeutic plasma concentrations are likely to be reached within 5 to 15 minutes after a 1 mg dose in an emergency. Because of the variability in the speed of absorption for IM & SC dosing, and the inability to titrate to effect, great care should be taken if repeated doses must be given by these routes. DISTRIBUTION Following a 1 mg parenteral dose, nalmefene was rapidly distributed. In a study of brain receptor occupancy, a 1 mg dose of nalmefene blocked over 80% of brain opioid receptors within 5 minutes after administration. The apparent volumes of distribution centrally (V c ) and at steady-state (V dss ) are 3.9 ± 1.1 L/kg and 8.6 ± 1.7 L/kg, respectively. Ultrafiltration studies of nalmefene have demonstrated that 45% (CV 4.1%) is bound to plasma proteins over a concentration range of 0.1 to 2 mcg/
the management of knownsuspected opioid overdosedepression
2022
30
OXYCONTIN
oxycodone hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug.
severepersistent painincluding immediate-release opioids in: Adults ()
2010
8
ZURNAI (AUTOINJECTOR)
nalmefene hydrochloride
Growth
INTRAMUSCULAR, SUBCUTANEOUS · SOLUTION
2024
0
Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 12 approved products, 2 clinical trials
Top TAs: Neurology, Metabolic Diseases
H-1B (2023): 2 approvals
Portfolio Health
Pre-Launch1 (8%)
Growth1 (8%)
Peak4 (33%)
LOE Approaching5 (42%)
Post-LOE1 (8%)
12 total products
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub